New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
07:20 EDTKPTIKaryopharm price target raised to $50 from $25 at JMP Securities
JMP Securities raised its price target on Karyopharm after it provided an outline of planned pivotal trials in AML, DLBCL, and Richterís syndrome, and formally stated that it is broadening its Phase II development plans in various solid tumor malignancies. The firm sees unmet need in these indications and its confidence in the company's chances of success has increased. It increased its estimate of peak U.S. sales for selinexor to $3.6B from $1.8B and reiterates an Outperform rating.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
11:11 EDTKPTIKaryopharm management to meet with Maxim
Subscribe for More Information
April 13, 2015
08:43 EDTKPTIKaryopharm granted U.S. composition-of-matter patent for selinexor
Karyopharm Therapeutics announced the issuance of U.S. Patent No. 8,999,996 entitled "Hydrazide Containing Nuclear Transport Modulators and Uses Thereof." This patent, which will expire in 2032 absent any patent term extensions, covers the composition-of-matter of Karyopharm's lead product candidate, selinexor, a first-in-class, oral SINE compound, as well as certain other compositions and related methods. Selinexor is being evaluated in multiple registration-directed and other later stage trials in patients with relapsed and/or refractory hematological and solid tumor malignancies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use